Quest Diagnostics Inc., of Madison, N.J., agreed to acquire Celera Corp., of Alameda, Calif., for $8 per share, or about $344 million, net of $327 million in acquired cash and short-term investments. The deal is expected to bolster Quest's molecular diagnostics work and add a pipeline of biomarkers for future development.